Journey Medical Corp (NASDAQ: DERM)

Journey Medical Corporation is a commercial stage pharmaceutical company that focuses on the sale and marketing of FDA approved prescription drugs for dermatological conditions in the United States. The company was incorporated in Delaware in 2014 and maintains its executive offices in Scottsdale Arizona. It is a controlled subsidiary of Fortress Biotech Inc. Journey Medical acquires rights to products and product candidates through licensing or other arrangements funds development and commercializes them through its field sales organization.

The company generates revenue primarily from the sale of its portfolio of FDA approved prescription drugs including Emrosi Qbrexza Accutane Amzeeq Zilxi and legacy products such as Exelderm Targadox Luxamend and the forthcoming anti itch product. It also receives royalty and milestone payments from licensing agreements such as the arrangement with Cutia Therapeutics (HK) Limited for the supply of Amzeeq in China. Additional revenue comes from upfront payments and milestone payments received under licensing out agreements such as the Maruho license for Qbrexza in Asian markets and the Cutia license for Amzeeq and Zilxi in Greater China. These licensing arrangements provide the company with non dilutive cash inflows that complement its product sales revenue.

The company operates in a competitive dermatology market that includes large and midsize players such as Galderma Laboratories Almirall Leo Pharma Mayne Pharma Botanix Pharmaceuticals and Ortho Dermatologics. Its competitive advantages derive from the commercial leadership of its management team which has over 135 years of collective sales and marketing experience and has launched brands that generated over three billion dollars in aggregate peak sales. The company also benefits from an experienced field sales force that covers more than eighty percent of dermatologists in the top fifty U. S. metropolitan statistical areas and reaches over seventy percent of the overall dermatology prescribing market. Journey Medical maintains a specialized distribution network that includes more than six hundred specialty pharmacies and wholesalers allowing it to deliver products directly to prescribers and patients. Several of its products Emrosi Qbrexza Amzeeq and Zilxi are protected by patents listed in the FDA Orange Book providing exclusivity and barriers to generic entry. The firm pursues an active business development strategy that seeks licensing acquisition and partnership opportunities to expand its pipeline and geographic reach.

The company sells its products to specialty pharmacies independent wholesalers distributors retail drug store chains independent pharmacies and managed care organizations such as health maintenance organizations group purchasing organizations nursing homes clinics pharmacy benefit management companies and mail order customers. It also supplies Cutia Therapeutics (HK) Limited for distribution in China and receives royalties on those sales. Additionally Journey Medical has a manufacturing and supply agreement with Epic Pharma LLC for the product Targadox although Epic Pharma acts as a supplier rather than an end user.